May 14, 2013
Bloomberg NewsEli Lilly and Co. CEO John Lechleiter underwent a scheduled surgery Monday for a heart defect, and the repair to the aorta
is functioning as intended, the Indianapolis-based drugmaker said.
More
June 23, 2011
Bloomberg NewsThe U.S. government needs to open its borders to attract and retain talented scientists for drugmakers to employ, Eli Lilly
& Co. CEO John Lechleiter plans to tell a technology conference Thursday.
More
March 16, 2011
J.K. WallEli Lilly and Co. CEO John Lechleiter visited Japan last week—three days before the massive earthquake—to deliver
his tried-and-true message: Drug companies need to reinvent invention, governments needs to support innovation, and Lilly
will be just fine after it has sustained the damage of the next three years.
More
February 5, 2011
Greg AndrewsCymbalta racked up $3.5 billion in sales last year, and some analysts say it may approach $5 billion before generic competition
arrives in 2013.
More
February 8, 2010
Peter Schnitzler, J.K. WallEli Lilly and Co. CEO John Lechleiter's total compensation increased $4.1 million in 2009.
More
September 14, 2009
J.K. WallSince John Lechleiter was named CEO 18 months ago, he's bet that Eli Lilly and Co. could face down its looming patent challenges
by launching innovative new medicines. Today's announcement of 5,500 job cuts by the end of 2011 and a restructuring of the
company's business units ups the ante on that bet, while indicating that it isn't working yet.
More
August 10, 2009
Kathleen McLaughlinAfter so many years of trying to tap every possible cubicle-dweller for donations, United Way of Central Indiana is putting
more effort into the richest veins in the workplace—the folks in corner offices.
More
July 28, 2009
Kathleen McLaughlinEli Lilly and Co. CEO John Lechleiter and his wife, Sarah, have pledged to give the United Way of Central Indiana a total
of $1 million over the next four years as a “challenge to CEOs and other community leaders to step up their giving.”
More
May 4, 2009
J.K. WallCompared with some of his pharmaceutical CEO peers these days, John Lechleiter has his company on a diet. Instead of using
a mega-merger to bulk up before the famine that patent expirations will bring on the industry next year,
Lechleiter has Eli Lilly and Co. burning management fat while looking for smaller companies to munch on.
More
December 24, 2007
J.K. WallJohn C. Lechleiter, whom Eli Lilly and Co.'s board voted to replace Sidney Taurel as CEO, is known for getting things done
and yet also for being good at analysis and relating to people under him. Taurel will step down at the end of March but remain
chairman until the end of 2008.
More
Can IBJ please stop referring to this property as "Kessler Mansion"? What a ridiculous title for the biggest, bloated, blight in our city. It's not a mansion. At best, it's an ideal site to shoot low-budget porn. Ahhh! Another business use!
Its stories like these that prove that a Ball State diploma is worth less than the paper that its printed on. A real institution of higher learning would have taken care of this long ago. No way should this crap be taught in a SCIENCE class.
It is such a shame that King Ballard has made Indianapolis into Chicago south with all of the rampant corruption.
How many of these 1,259 bills were actually heard and voted on on the floor vs how many were shot down in committee?
When a an arrogant young guy with essentially no experience and no qualifications for the job, was dropped into an Administrator position out of nowhere by his "mentor" in the Mayor's office things seemed fishy. Sometimes things are what they seem.